University of Alabama at Birmingham-Developed Glioma Drug Shows Promise in Phase 1 Trial
BIRMINGHAM, Ala. – A drug developed and tested at UAB (University of Alabama at Birmingham) targeted at malignant brain tumors known as glioma has shown promising results in a Phase 1 trial, according to results presented at the American Society for Therapeutic Radiology and Oncology annual meeting. The findings indicate that an intravenous formulation of TM-601 can cross the blood brain-barrier and bind to tumor tissue in the brain. TM-601 is a synthetic version of chlorotoxin, a naturally occurring peptide derived from scorpion venom. It was developed by scientists at UAB and TransMolecular, Inc., a biotechnology company which funded the current study.